-
1
-
-
0023232859
-
Critical issues in cyclosporine monitoring: Report of the task force on cyclosporine monitoring
-
Shaw LM, Bowers L, Demers L, et al. Critical issues in cyclosporine monitoring: report of the task force on cyclosporine monitoring. Clin Chem 1987;33:1269-88.
-
(1987)
Clin Chem
, vol.33
, pp. 1269-1288
-
-
Shaw, L.M.1
Bowers, L.2
Demers, L.3
-
3
-
-
0027226147
-
Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation
-
Lindholm A, Kaham BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993;54:205-18.
-
(1993)
Clin Pharmacol Ther
, vol.54
, pp. 205-218
-
-
Lindholm, A.1
Kaham, B.D.2
-
4
-
-
0036766650
-
Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: Patients monitored by absorption profiling
-
Clase CM, Mahalati K, Kiberd BA, et al. Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling. Am J transplant 2002;2:789-95.
-
(2002)
Am J Transplant
, vol.2
, pp. 789-795
-
-
Clase, C.M.1
Mahalati, K.2
Kiberd, B.A.3
-
5
-
-
0028244432
-
Population approaches in drug development: Report on expert meeting to discuss population pharmacokinetic/pharmacodynamic software
-
Aarons L, Balant LP, Mentre F, et al. Population approaches in drug development: report on expert meeting to discuss population pharmacokinetic/ pharmacodynamic software. Eur J Clin Pharmacol 1994;46:389-91.
-
(1994)
Eur J Clin Pharmacol
, vol.46
, pp. 389-391
-
-
Aarons, L.1
Balant, L.P.2
Mentre, F.3
-
6
-
-
0028215664
-
Evaluation of a Bayesian approach to the pharmacokinetic interpretation of cyclosporine concentrations in renal allograft recipients
-
Anderson JE, Munday AS, Kelman AW, et al. Evaluation of a Bayesian approach to the pharmacokinetic interpretation of cyclosporine concentrations in renal allograft recipients. Ther Drug Monit 1994;16:160-5.
-
(1994)
Ther Drug Monit
, vol.16
, pp. 160-165
-
-
Anderson, J.E.1
Munday, A.S.2
Kelman, A.W.3
-
9
-
-
0027160160
-
Pharmacokinetics of cyclosporine in heart and lung transplant candidates and recipients with cystic fibrosis and Eisenmenger's syndrome
-
Tan Trull KKCAK, Hue KL, Best NG, Wallwork J, Higenbottam TW. Pharmacokinetics of cyclosporine in heart and lung transplant candidates and recipients with cystic fibrosis and Eisenmenger's syndrome. Clin Pharmacol Ther 1993;53:544-54.
-
(1993)
Clin Pharmacol Ther
, vol.53
, pp. 544-554
-
-
Kkcak, T.T.1
Hue, K.L.2
Best, N.G.3
Wallwork, J.4
Higenbottam, T.W.5
-
10
-
-
0031838725
-
NONMEM population pharmacokinetic modeling of orally administered cyclosporine from routine drug monitoring data after heart transplantation
-
Parke J, Charles, BG. NONMEM population pharmacokinetic modeling of orally administered cyclosporine from routine drug monitoring data after heart transplantation. Ther Drug Monit 1998;20:284-93.
-
(1998)
Ther Drug Monit
, vol.20
, pp. 284-293
-
-
Parke, J.1
Charles, B.G.2
-
11
-
-
10344264967
-
Pharmacokinetics of immunosuppressants: A perspective on ethnic differences
-
Dirks NL, Huth B, Yates CR, Meibohm B. Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. Int J Clin Pharmacol Ther 2004;42:701-18.
-
(2004)
Int J Clin Pharmacol Ther
, vol.42
, pp. 701-718
-
-
Dirks, N.L.1
Huth, B.2
Yates, C.R.3
Meibohm, B.4
-
12
-
-
3242723840
-
The MDR1 (ABCB1) gene polymorphism and its clinical implications
-
Ieiri I, Takane H, Otsubo K. The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin Pharmacokinet 2004;43:553-76.
-
(2004)
Clin Pharmacokinet
, vol.43
, pp. 553-576
-
-
Ieiri, I.1
Takane, H.2
Otsubo, K.3
-
13
-
-
0035217180
-
The genetic determinants of the CYP3A5 polymorphism
-
Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001;11:773-9.
-
(2001)
Pharmacogenetics
, vol.11
, pp. 773-779
-
-
Hustert, E.1
Haberl, M.2
Burk, O.3
-
14
-
-
0035068952
-
Pharmacokinetics of cyclosporine in heart recipients receiving metabolic inhibitors
-
Akhlaghi F, Keogh AM, McLachlan AJ, Kann A. Pharmacokinetics of cyclosporine in heart recipients receiving metabolic inhibitors. J Heart Lung Transplant 2001;20:431-8.
-
(2001)
J Heart Lung Transplant
, vol.20
, pp. 431-438
-
-
Akhlaghi, F.1
Keogh, A.M.2
McLachlan, A.J.3
Kann, A.4
-
15
-
-
0036754192
-
A limited sampling strategy for the estimation of 12-hour Neoral systemic drug exposure in heart transplant recipients
-
Balram C, Sivathasan C, Cheung YB, Tan SB, Tan YS. A limited sampling strategy for the estimation of 12-hour Neoral systemic drug exposure in heart transplant recipients. J Heart Lung Transplant 2002;21:1016-21.
-
(2002)
J Heart Lung Transplant
, vol.21
, pp. 1016-1021
-
-
Balram, C.1
Sivathasan, C.2
Cheung, Y.B.3
Tan, S.B.4
Tan, Y.S.5
-
16
-
-
0030953226
-
Stability and performance of a population pharmacokinetic model
-
Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 1997;37:486-95.
-
(1997)
J Clin Pharmacol
, vol.37
, pp. 486-495
-
-
Ette, E.I.1
-
17
-
-
0033120135
-
A procedure for generating samples for the validation of nonlinear mixed-effects population models
-
Parke J, Holford NHG, Charles BG. A procedure for generating samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 1999;59:19-29.
-
(1999)
Comput Methods Programs Biomed
, vol.59
, pp. 19-29
-
-
Parke, J.1
Holford, N.H.G.2
Charles, B.G.3
-
18
-
-
0028102629
-
Pharmacokinetics of cyclosporine in renal transplant patients on diltiazem
-
Masri MA, Shakuntala V, Shanwaz M, et al. Pharmacokinetics of cyclosporine in renal transplant patients on diltiazem. Transplant Proc 1994;26:1921.
-
(1994)
Transplant Proc
, vol.26
, pp. 1921
-
-
Masri, M.A.1
Shakuntala, V.2
Shanwaz, M.3
-
19
-
-
0030665572
-
Diltiazem-cyclosporin pharmacokinetic interaction: Dose-response relationship
-
Jones TE, Morris RG, Mathew TH. Diltiazem-cyclosporin pharmacokinetic interaction: dose-response relationship. Br J Clin Pharmacol 1997;44:499-504.
-
(1997)
Br J Clin Pharmacol
, vol.44
, pp. 499-504
-
-
Jones, T.E.1
Morris, R.G.2
Mathew, T.H.3
-
20
-
-
0031875225
-
Effect of metabolic inhibitors on cyclosporin pharmacokinetics using a population approach
-
Mclachlan AJ, Tett SE. Effect of metabolic inhibitors on cyclosporin pharmacokinetics using a population approach. Ther Drug Monit 1998;20:390-5.
-
(1998)
Ther Drug Monit
, vol.20
, pp. 390-395
-
-
Mclachlan, A.J.1
Tett, S.E.2
-
21
-
-
0025168996
-
Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem
-
Pichard L, Gillet G, Fabre I, et al. Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. Drug Metab Dispos 1990;18:711-19.
-
(1990)
Drug Metab Dispos
, vol.18
, pp. 711-719
-
-
Pichard, L.1
Gillet, G.2
Fabre, I.3
-
22
-
-
0033978102
-
Extensive metabolism of diltiazem and P-glycoprotein-mediated efflux of desacetyl-diltiazem by rat jejunum in vitro
-
Molden E, Christensen H, Sund RB. Extensive metabolism of diltiazem and P-glycoprotein-mediated efflux of desacetyl-diltiazem by rat jejunum in vitro. Drug Metab Dispos 2000;28:107-9.
-
(2000)
Drug Metab Dispos
, vol.28
, pp. 107-109
-
-
Molden, E.1
Christensen, H.2
Sund, R.B.3
-
23
-
-
0023921505
-
Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine metabolizing enzyme explaining interactions of cyclosporine with other drugs
-
Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine metabolizing enzyme explaining interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988;43:630-5.
-
(1988)
Clin Pharmacol Ther
, vol.43
, pp. 630-635
-
-
Kronbach, T.1
Fischer, V.2
Meyer, U.A.3
-
24
-
-
12644272784
-
Role of intestinal p-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine
-
Lown KS, Mayo RR, Leichtmann AB, et al. Role of intestinal p-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997;62:248-60.
-
(1997)
Clin Pharmacol Ther
, vol.62
, pp. 248-260
-
-
Lown, K.S.1
Mayo, R.R.2
Leichtmann, A.B.3
-
25
-
-
0000934767
-
The molecular basis of cyclosporine a metabolism, pharmacokinetics and drug interactions
-
Watkins PB, Leichtman A. The molecular basis of cyclosporine A metabolism, pharmacokinetics and drug interactions. Graft 1999;2:177-81.
-
(1999)
Graft
, vol.2
, pp. 177-181
-
-
Watkins, P.B.1
Leichtman, A.2
-
26
-
-
0026488174
-
Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: Racial differences in bioavailability
-
Lindholm A, Welsh M, Alton C, Kahan BD. Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability. Clin Pharmacol Ther 1992;52:359-71.
-
(1992)
Clin Pharmacol Ther
, vol.52
, pp. 359-371
-
-
Lindholm, A.1
Welsh, M.2
Alton, C.3
Kahan, B.D.4
-
27
-
-
0023695932
-
Blood cyclosporine pharmacokinetics in patients undergoing marrow transplantation: Influence of age, obesity and hematocrit
-
Yee GC, McGuire TR, Gmur DJ, Lennon TP, Deeg HJ. Blood cyclosporine pharmacokinetics in patients undergoing marrow transplantation: influence of age, obesity and hematocrit. Transplantation 1988;46:399-402.
-
(1988)
Transplantation
, vol.46
, pp. 399-402
-
-
Yee, G.C.1
McGuire, T.R.2
Gmur, D.J.3
Lennon, T.P.4
Deeg, H.J.5
-
28
-
-
0024600607
-
Influence of demographic factors on cyclosporine pharmacokinetics in adult uremic patients
-
Grevel J, Reynolds KL, Rutzky LP, Kahan BD. Influence of demographic factors on cyclosporine pharmacokinetics in adult uremic patients. J Clin Pharmacol 1989;29:261-6.
-
(1989)
J Clin Pharmacol
, vol.29
, pp. 261-266
-
-
Grevel, J.1
Reynolds, K.L.2
Rutzky, L.P.3
Kahan, B.D.4
-
29
-
-
10044294681
-
Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes
-
Hesselink DA, van Gelder T, van Schaik RH, et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004;76:545-56.
-
(2004)
Clin Pharmacol Ther
, vol.76
, pp. 545-556
-
-
Hesselink, D.A.1
Van Gelder, T.2
Van Schaik, R.H.3
-
30
-
-
0036174324
-
Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporine microemulsion in renal transplant recipients
-
Schadeli F, Marti HP, Frey FJ, Uehlinger DE. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporine microemulsion in renal transplant recipients. Clin Pharmacokinet 2002;41:59-69.
-
(2002)
Clin Pharmacokinet
, vol.41
, pp. 59-69
-
-
Schadeli, F.1
Marti, H.P.2
Frey, F.J.3
Uehlinger, D.E.4
-
31
-
-
0031957498
-
Ability of a first-pass pharmacokinetic model to characterize cyclosporine blood concentrations after administrations of Sandimmune or Neoral formulations
-
Ducharme MP, Verret L, Brouillette D, Sirois G. Ability of a first-pass pharmacokinetic model to characterize cyclosporine blood concentrations after administrations of Sandimmune or Neoral formulations. Ther Drug Monit 1998;20:165-71.
-
(1998)
Ther Drug Monit
, vol.20
, pp. 165-171
-
-
Ducharme, M.P.1
Verret, L.2
Brouillette, D.3
Sirois, G.4
-
32
-
-
0034973958
-
Application of a Gamma model of absorption to oral cyclosporine
-
Debord J, Risco E, Harel M, et al. Application of a Gamma model of absorption to oral cyclosporine. Clin Pharmacokinet 2001;40:375-82.
-
(2001)
Clin Pharmacokinet
, vol.40
, pp. 375-382
-
-
Debord, J.1
Risco, E.2
Harel, M.3
-
33
-
-
16244408050
-
Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients
-
Rosenbaum SE, Baheti G, Trull AK, Akhlaghi F. Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. Ther Drug Monit 2005;27:116-22.
-
(2005)
Ther Drug Monit
, vol.27
, pp. 116-122
-
-
Rosenbaum, S.E.1
Baheti, G.2
Trull, A.K.3
Akhlaghi, F.4
|